Asthma Management Guidelines

Initial Assessment and Classification

Asthma severity should be classified as intermittent or persistent (mild, moderate, or severe) based on symptoms, nighttime awakenings, rescue medication use, activity limitation, and lung function, as recommended by the American Academy of Family Physicians 1
Treatment decisions should consider both current impairment (day-to-day symptoms) and future risk (exacerbations), according to the American College of Allergy, Asthma, and Immunology and the Mayo Clinic 2, 3

For persistent asthma, low-dose inhaled corticosteroids (ICSs) are the preferred controller medication, as recommended by the American College of Allergy, Asthma, and Immunology 3
For moderate persistent asthma, the preferred treatment is low-dose ICS plus long-acting beta-agonist (LABA), as recommended by the American Academy of Family Physicians 1
For severe persistent asthma, the preferred treatment is high-dose ICS plus LABA, as recommended by the American Academy of Family Physicians 1

The American Academy of Allergy, Asthma, and Immunology recommends dividing treatment recommendations into three age groups: children under 5 years, children 5-11 years, and patients 12 years and older 4, 2
LABAs should never be used as monotherapy due to increased risk of severe exacerbations and death, as warned by the American College of Allergy, Asthma, and Immunology 4
The American Academy of Family Physicians recommends assessing asthma control at regular intervals using validated tools like the Asthma Control Test 1, 5

The American Academy of Family Physicians recommends stepping up therapy if needed (after checking adherence, inhaler technique, and environmental triggers) 1
The American Academy of Family Physicians also recommends stepping down therapy if asthma is well-controlled for at least three months 1
Consider referral to an asthma specialist for patients requiring Step 4 care or higher, as recommended by the American Academy of Family Physicians 1

For patients with moderate-to-severe persistent asthma, combination therapy with ICS/LABA remains recommended despite the black box warning about LABA risks, as stated by the American College of Allergy, Asthma, and Immunology 4

The American College of Physicians recommends using as-needed combination low-dose ICS-formoterol as the reliever medication, providing both symptom relief and anti-inflammatory protection with each use 6
The Mayo Clinic suggests that using SABA as the reliever medication alongside a separate ICS inhaler is less preferred due to the risk of SABA overuse without adequate anti-inflammatory coverage 6
The American Academy of Family Physicians advises providing patients with a written asthma action plan, including daily medications, recognition of worsening symptoms, medication adjustments during exacerbations, and when to seek emergency care 7
The American Academy of Family Physicians recommends monitoring for overuse of SABA, with more than one canister per month indicating the need to increase controller therapy 7

The American College of Allergy, Asthma, and Immunology suggests that biologic therapy, such as omalizumab, may be added for patients aged 12 years and older with allergic asthma inadequately controlled on high-dose ICS/LABA 6